

# College of American Pathologists (CAP) GH2 Survey Data:

(updated 12/09)

The American Diabetes Association (ADA) recommends that laboratories use only HbA1c assay methods that have been NGSP certified and report results as “%HbA1c” or “%HbA1c equivalents”. The ADA also recommends that all laboratories performing HbA1c testing participate in the College of American Pathologists (CAP) fresh sample proficiency testing survey (see ADA Recommendations section on this website for more details).

CAP GH2 data for the first survey of 2009 are summarized below. The NGSP target or reference values are based on replicate analyses using seven NGSP certified secondary reference methods.

## 2009 GH2-B (fresh pooled samples)

\* = NGSP certified at the time of the survey

		GH2-04			GH2-05			GH2-06		
NGSP Reference Value <sup>†</sup>		6.6			9.5			7.4		
	No. Labs	Mean	Bias	%CV	Mean	Bias	%CV	Mean	Bias	%CV
* Abbott Architect	50	6.73	0.13	4.5	9.62	0.12	4.2	7.7	0.3	5.4
* Beckman Synchron CX Systems	27	6.45	-0.15	5.1	9.21	-0.29	5.6	7.18	-0.22	5.5
* Beckman Synchron LX Systems	87	6.49	-0.11	3.8	9.23	-0.27	3.5	7.1	-0.3	3.9
* Beckman UniCel DxC Synchron	269	6.43	-0.17	3.6	9.18	-0.32	3.4	7.06	-0.34	3.6
* Bio-Rad D-10	209	6.74	0.14	2.9	9.54	0.04	2.8	7.6	0.2	3.2
* Bio-Rad Variant II	139	6.81	0.21	2.8	9.75	0.25	2.7	7.67	0.27	3.4
* Bio-Rad Variant II Turbo	147	6.76	0.16	2.9	9.45	-0.05	2.4	7.58	0.18	2.6
* Metrika A1cNOW <sup>#</sup>	19	5.98	-0.62	7.9	8.51	-0.99	6.5	6.72	-0.68	6
* Olympus AU system	25	6.46	-0.14	4.4	9.24	-0.26	4.8	7.32	-0.08	4.8
* Roche Cobas c501	133	6.70	0.10	3	9.29	-0.21	3.7	7.35	-0.05	3.7
* Roche Cobas Integra 400	38	6.87	0.27	3.6	9.75	0.25	2.4	7.71	0.31	3.3
* Roche Cobas Integra 800	139	6.78	0.18	3.2	9.59	0.09	2.8	7.55	0.15	3.3
* Roche/Hitachi Modular P	15	6.61	0.01	3.5	9.18	-0.32	3.3	7.27	-0.13	4.4
* Siemens Advia Chemistry (new)	21	6.41	-0.19	7.6	9.00	-0.50	3.4	6.98	-0.42	9.7
* Siemens Advia Chemistry (original)	26	6.79	0.19	3.8	9.31	-0.19	4.1	7.54	0.14	4.1
* Siemens DCA 2000/2000+	106	6.81	0.21	2.5	9.48	-0.02	3	7.56	0.16	3.1
* Siemens DCA Vantage	97	6.78	0.18	2.8	9.39	-0.11	3.4	7.55	0.15	2.5
* Siemens Dimension ExL	25	6.62	0.02	4.6	9.32	-0.18	5	7.28	-0.12	5.2
* Siemens Dimension RxL	349	6.67	0.07	3.3	9.41	-0.09	4.4	7.29	-0.11	3.7
Siemens Dimension Vista	36	6.84	0.24	6.5	9.21	-0.29	2.4	7.45	0.05	4.4
* Siemens Dimension Xpand	141	6.60	0.00	3.3	9.37	-0.13	4.9	7.23	-0.17	3.7
* Tosoh A1c 2.2 Plus	71	6.87	0.27	3.1	9.63	0.13	2.8	7.73	0.33	3
* Tosoh G7 Auto HPLC	248	6.80	0.20	1.9	9.53	0.03	1.8	7.67	0.27	2.3
* Tosoh G8 Auto HPLC	84	6.80	0.20	1.7	9.52	0.02	1.5	7.63	0.23	1.9
* Trinity Biotech HPLC (Affinity)	27	6.66	0.06	3.4	9.46	-0.04	3.9	7.36	-0.04	3.4
* Vitros 5,1 FS Chem Syst	124	6.80	0.20	4.1	9.58	0.08	3.7	7.55	0.15	4.2

<sup>†</sup> Assigned as the mean of 3 replicate analyses per day for two days per method using 7 NGSP certified secondary reference methods.

<sup>#</sup> EDTA in the CAP sample has been shown by the manufacturer of A1cNow+ to cause artificially low results by this method. Routine samples for this method are from fingerstick and do not include EDTA. The manufacturer recommends the use of heparin anticoagulant instead of EDTA when testing venous samples

**Commentary by R. Little, Ph.D., NGSP Network Coordinator for the NGSP Steering Committee**

**In 2009, based on data from the GH2-B survey:**

- Only HbA1c results are included in this CAP survey report. Laboratories reporting total GHB are not included.
- Some methods are divided into smaller groups, e.g. the three Beckman instruments are listed separately but some are grouped together (e.g. Trinity Biotech CLC385, CLC ultra2, PDQ).
- Bias from the NGSP target and variability ( $\pm 2SD$ ) are shown in *figure 1* for each method. Other than the Metrika A1cNow<sup>#</sup> (see footnote above), the method-specific medians were all within 0.3, 0.5 and 0.5% HbA1c of NGSP targets at the low, mid and high HbA1c levels, respectively (table above). Many methods showed less than 0.3% HbA1c bias for all levels.
- Method-specific, between-laboratory CV's ranged from 1.5% to 9.7%. Only the Beckman CX and the Metrika A1cNow showed between-laboratory CVs >5% at all three levels. Two methods showed CVs >5% for 2 levels. However, approximately 93% of laboratories were using methods that had between-lab CVs  $\leq 5.0\%$  at all three HbA1c levels.
- This is the sixth GH2 survey using an accuracy based target (NGSP); peer group means are no longer used for grading the GH2 survey (except for the Metrika method due to its EDTA interference). The acceptable limit for this survey is  $\pm 10\%$  of the target value; the acceptable limit for grading will be reduced to  $\pm 8\%$  in 2010 and possibly  $\pm 6\%$  in 2011. The cumulative pass rate for this survey ranged from 97.5% to 98.1%, depending upon the HbA1c level. For individual methods, the lowest pass rate was 80.6% and the highest was 100% (Sacks, Chemistry Resource Committee, CAP GH2-B 2009). Methods with small bias and low CVs will have the highest pass rates and, conversely, methods with large bias and/or high CVs will have the lowest pass rates.
- *Figures 2 and 3* examine the bias (fig 2) and CV (fig 3) trends for the 2006 through 2009B surveys for the 11 most used methods. The survey samples are now grouped by HbA1c level: Low Level: 5-6.6% HbA1c, Medium Level: 6.8-9.5% HbA1c. For these graphs the methods are combined by group, e.g. data for all the Dimension instruments are combined. In one case (Roche Cobas, medium HbA1c levels) where one instrument gave a positive bias and the other of the same type gave a negative bias, no result is provided on the graph. Generally, there appears to be a decrease in the overall bias and within-method variability (CV) over time.

*NOTE: The NGSP evaluates agreement at the manufacturing site using one lot of reagents and calibrators, one instrument, and one application under optimal conditions. CAP precision reflects between-laboratory reproducibility, often with more than one lot of reagents and calibrators, and sometimes with different instruments (e.g. Cobas Integra 400 & Cobas Integra 700) and/or different applications (e.g. Cobas Integra hemolysate or whole blood application). In addition, if changes were made in the method just prior to NGSP certification, it is possible that not all participating laboratories in the field would have made the change at the time of the CAP survey. For these reasons, it is important that laboratorians review not only the certification status of GHB methods but also their performance in the CAP survey over time (a good indication of field performance) when selecting or evaluating GHB assay methods.*

Figure 1






Figure 2: Bias Trend by Method



**Figure 3: %CV Trend by Method**

